Hepatic and Extrahepatic Cancer in Cirrhosis: A Longitudinal Cohort Study

Berman, Kenneth; Tandra, Sweta; Vuppalanch, Raj; Ghabril, Marwan; Sandrasegaran, Kumaresan; Nguyen, James; Caffrey, Helena M.; Liangpunsakul, Suthat; Lumeng, Lawrence; Kwo, Paul Y.; Chalasani, Naga

doi:10.1038/ajg.2010.477

Cited by 31 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a retrospective cohort study by Berman et al. [43], the patients with cirrhosis due to a combination of HCV and alcohol had a significantly higher risk of HCC than those with cirrhosis due to alcohol alone (HR 11.2; 95% CI 2.3–55.0). Patients with HCV and alcohol exposure had a reduced tumor-free survival compared with those with HCV alone [44].…”

Section: Risk Factors For Hccmentioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

View full text Add to dashboard Cite

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

show abstract

Section: Risk Factors For Hccmentioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

View full text Add to dashboard Cite

show abstract

“…1,4,12,13,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] Yet, no previous reports have assessed long-term outcomes between patients with NASH and other CLDs within a framework of multimodal curative therapy, including liver transplantation, resection, and ablation. Thus, the aim of this study was to determine the differences in clinical presentation, histopathology, and survival outcomes among patients undergoing any curative therapy for HCC in the setting of NASH compared to hepatitis C (HCV) and/or alcoholic liver disease (ALD).…”

mentioning

confidence: 99%

“…1,2,[8][9][10][14][15][16] Despite a lower incidence of HCC resulting from NASH compared to other CLDs, the high prevalence of NAFLD means that a large percentage of HCC is caused by NASH. [11][12][13][17][18][19][20][21][22] Multiple reports describe the natural history of patients with NASH compared to other CLDs, the Abbreviations: AASLD, American Association for the Study of Liver Diseases; AFP, alpha-fetoprotein; AJCC, American Joint Committee on Cancer; ALD, alcoholic liver disease; BMI, body mass index; DM, diabetes mellitus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; INR, international normalized ratio; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; MELD, model for end-stage liver disease; OS, overall survival; RFA, radiofrequency ablation; RFS, recurrence-free survival; TACE, transarterial chemoembolization; Y-90, yittrium-90 radioembolization.…”

mentioning

confidence: 99%

Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease

et al. 2012

View full text Add to dashboard Cite

Concomitant increasing incidences of hepatocellular carcinoma (HCC) and nonalcoholic steatohepatitis (NASH) suggest that a substantial proportion of HCC arises as a result of hepatocellular injury from NASH. The aim of this study was to determine differences in severity of liver dysfunction at HCC diagnosis and long-term survival outcomes between patients undergoing curative therapy for HCC in the background of NASH compared to hepatitis C virus (HCV) and/or alcoholic liver disease (ALD). Patient demographics and comorbidities, clinicopathologic data, and long-term outcomes among patients who underwent liver transplantation, hepatic resection, or radiofrequency ablation for HCC were reviewed. From 2000 to 2010, 303 patients underwent curative treatment of HCC; 52 (17.2%) and 162 (53.5%) patients had NASH and HCV and/or alcoholic liver disease. At HCC diagnosis, NASH patients were older (median age 65 versus 58 years), were more often female (48.1% versus 16.7%), more often had the metabolic syndrome (45.1% versus 14.8%), and had lower model for end-stage liver disease scores (median 9 versus 10) (all P < 0.05). NASH patients were less likely to have hepatic bridging fibrosis or cirrhosis (73.1% versus 93.8%; P < 0.001). After a median follow-up of 50 months after curative treatment, the most frequent cause of death was liver failure. Though there were no differences in recurrence-free survival after curative therapy (median, 60 versus 56 months; P 5 0.303), NASH patients had longer overall survival (OS) (median not reached versus 52 months; P 5 0.009) independent of other clinicopathologic factors and type of curative treatment. Conclusion: Patients with HCC in the setting of NASH have less severe liver dysfunction at HCC diagnosis and better OS after curative treatment compared to counterparts with HCV and/or alcoholic liver disease. (HEPATOLOGY 2012;55:1809-1819 C oncomitant increases in the incidence of hepatocellular carcinoma (HCC) and prevalence of nonalcoholic fatty liver disease (NAFLD) suggest that a substantial proportion of HCC arises as a result of hepatocellular injury from nonalcoholic steatohepatitis (NASH). As a result, HCC is the most rapidly increasing cause of cancer death in the United States.

show abstract

“…According to recent studies, patients with liver cirrhosis are not only at an increased risk of HCC, but also at an increased risk of extrahepatic cancers [9]. Breast, lung, and colon cancers and lymphoma are common extra-hepatic cancers.…”

Section: Discussionmentioning

confidence: 99%

Primary Follicular Lymphoma in a Male Breast: A Case Report

et al. 2014

View full text Add to dashboard Cite

Primary breast lymphoma (PBL) is a rare disease, particularly in males. Diffuse large B cell lymphoma is the most common PBL, while follicular lymphoma is less common. Furthermore, primary follicular lymphoma of a male breast is rarely reported. We report a male patient with primary follicular lymphoma of the breast and hepatocellular carcinoma (HCC). A 46-year-old man was diagnosed with liver cirrhosis secondary to chronic hepatitis B infection. Ten years later, he underwent segmentectomy of the liver due to HCC. Another 5 months later, he presented with a painless mass in the right chest wall. The mass was diagnosed as follicular lymphoma of the breast. The stage was IEA and he did not receive adjuvant therapy. Although only a few cases have been reported, lymphoma should be considered as a possible cause of breast mass, even in male patients.

show abstract

Hepatic and Extrahepatic Cancer in Cirrhosis: A Longitudinal Cohort Study

Abstract: This study furthers our understanding of HCC and EHC risk in cirrhosis. If confirmed by other studies, these data will assist in developing optimal strategies for monitoring of cancer in individuals with cirrhosis.

Cited by 31 publications

References 25 publications

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease

Primary Follicular Lymphoma in a Male Breast: A Case Report

Contact Info

Product

Resources

About